The authors who contributed to this publication have disclosed the following industry relationships:
Richard M. Bergenstal, MD, is a clinical investigator at the International Diabetes Center at Park Nicollet. Dr. Bergenstal does clinical trials, consults, receives institutional support for educational activities or participates on a scientific advisory board for Eli Lilly & Co., Novo Nordisk, sanofi-aventis, Medtronic, Abbott Diabetes Care, MannKind, Merck, Roche, Amylin, Pfizer, ResMed, Bayer, Valeritas, Novartis, UnitedHealth Group and LifeScan. He has inherited Merck stock. All research activity, advisory/consultancy work and educational services are performed under contract to the non-profit Park Nicollet Institute and the International Diabetes Center. Dr. Bergenstal receives no personal compensation for these activities.
Robert M. Cuddihy, MD, is a clinical investigator at the International Diabetes Center at Park Nicollet. Dr. Cuddihy serves as a consultant for Novo Nordisk, Bayer, Roche Diagnostics, an investigator for Amylin, Eli Lilly & Co., Novo Nordisk, ResMed, sanofi-aventis, Mannkind, Medtronic, Bayer, and Abbott Diabetes, and receives institutional support for educational activities from Eli Lilly & Co., Lifescan, and Novartis. All research activity, advisory/consultancy work and educational services are performed under contract to the non-profit Park Nicollet Institute and the International Diabetes Center. Dr. Cuddihy receives no personal compensation for these activities.
Vivian A. Fonseca, MD, has received research grants (to Tulane University) from GlaxoSmithKline, Novartis, Novo Nordisk, Takeda, Astra-Zeneca, Pfizer, sanofi-aventis, Eli Lilly & Co., Daiichi Sankyo, NIH, and ADA. He has received honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Novo Nordisk, sanofi-aventis, Eli Lilly & Co., and Daiichi Sankyo.
Matthew P. Gilbert, DO, MPH, has no financial arrangement or affiliation with a corporate organization or manufacturer of a product discussed in this supplement.
Robert R. Henry, MD, has received research grants, managed by the Veterans Medical Research Foundation or University of California San Diego from Amylin, Bristol Myers-Sqibb, GlaxoSmithKline, Eli Lilly & Co., Merck, Novartis, Novo Nordisk, Roche, Sankyo, and Veralight. He has served as a consultant for Amylin, AstraZenica, Bristol Myers-Squibb, GlaxoSmithKline, Eli Lilly & Co., Merck, Novartis, Novo Nordisk, Roche, Sankyo, sanofi-aventis and Takeda. He is a member the Speakers' Bureau for GlaxoSmithKline, Merck, Novo Nordisk, Sankyo and Takeda and owns pension stock in GlaxoSmithKline, Merck, Schering Plough, and Pfizer. Dr. Henry's manuscript was supported by the Department of Veteran Affairs. (Dr. Henry is employed by the Department of Veteran affairs).
David M. Kendall, MD, is a clinical investigator at the International Diabetes Center (IDC) at Park Nicollet. IDC receives research support from Abbott Diabetes Care, Amylin Pharmaceuticals, Bayer Diabetes Care, Dexcom, Eli Lilly & Co., Hoffman La Roche, MannKind, Merck, Minimed-Medtronic, Novo Nordisk, ResMed, Sanofi-Aventis; he is a consultant and performs scientific and clinical advisory board activity for Amylin Pharmaceuticals, Daiichi Sankyo, Eli Lilly & Co., HealthPartners, Intarcia, Nektar Therapeutics, and Takeda; He has received education funding and performed professional services for Amylin Pharmaceuticals, Bayer Diabetes Care, Eli Lilly & Co., Merck, Novartis, sanofi-aventis, and UnitedHealth Group. All research activity, advisory/consultancy work and educational services are performed under contract to the non-profit Park Nicollet Institute and the International Diabetes Center. Dr. Kendall receives no personal compensation for these activities.
Sunder Mudaliar, MD, is on the Speakers' Bureau for Takeda Pharmaceuticals and has received research grant support managed by the Veterans Medical Research Foundation from GlaxoSmithKline and sanofi-aventis. Dr. Mudaliar's manuscript was supported by the Department of Veteran Affairs. (Dr. Mudaliar is employed by the Department of Veteran affairs).
Michael A. Nauck, MD, PhD, is a member of the advisory boards of Amylin Pharmaceuticals, ConjuChem, Eli Lilly & Co., GlaxoSmithKline, Hoffman La Roche, Novartis Pharma, NovoNordisk, Probiodrug, Restoragen (BioNebraska), sanofi-aventis Pharma. He has received honorarium or consulting fees from AstraZeneca, Bayer Vital Pharma, Berlin Chemie/Menarini, Biovitrum, ConjuChem, Eli Lilly & Co., Hoffman La Roche, Merck, MSD, Novartis Pharma, Novo Nordisk, Pfizer, Probiodrug, Restoragen (BioNebraska), sanofi-aventis Pharma, Takeda. He has received grants and research support from Amylin Pharmaceuticals, Bayer Vital Pharma, Leverkusen, Eli Lilly & Co., Menarini/Berlin-Chemie, Novartis Pharma, Novo Nordisk, sanofi-aventis Pharma, Probiodrug, Restoragen (BioNebraska).
Richard E. Pratley, MD, has received research grants and participated in clinical trials for Takeda, GlaxoSmithKline, Novartis, Merck, Eli Lilly & Co., and sanofi-aventis. He is on the consulting and advisory boards of Takeda, GlaxoSmithKline, Novartis, Roche, and Novo Nordisk. He is also on the speakers' panels of Merck, Novo Nordisk, Takeda, and Novartis. He owns stock in Novartis.
FULL TEXT